CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
4.370
-0.200 (-4.38%)
Dec 5, 2025, 4:00 PM EST - Market closed
CalciMedica Employees
CalciMedica had 14 employees as of December 31, 2024. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change
2
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,647,143
Market Cap
62.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | 2 | 16.67% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CALC News
- 23 days ago - CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PRNewsWire
- 23 days ago - CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension - PRNewsWire
- 25 days ago - CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025 - PRNewsWire
- 7 weeks ago - CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™ - PRNewsWire
- 3 months ago - CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 4 months ago - CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PRNewsWire
- 5 months ago - CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - PRNewsWire
- 5 months ago - CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure - PRNewsWire